

P21480

Application No. 09/926,218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Arne HOLMGREN et al.

Group Art Unit : 1621

Appl. No : 09/926,218  
(National Stage of PCT/JP00/02076)

Examiner : Kumar

I.A. Filed : March 31, 2000

For : SUBSTRATE FOR THIOREDOXIN REDUCTASE

**FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, **Mail Stop Issue Fee**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

Further to the previously filed Information Disclosure Statements, Applicants hereby submit a copy of a European Office Action mailed November 25, 2009 in connection with the counterpart European application.

Applicants note that this European Office Action cites the following documents:

1. U.S. Patent No. 4,618,669
2. U.S. Patent No. 4,730,053
3. Parnham M.J., "The Pharmaceutical Potential of Seleno Organic Compounds" Expert Opinion on Investigational Drugs, Ashley Publications Ltd., GB, Vol. 5, No.7, 1 July 1996, pages 861-870, XP000645626 ISSN: 1354-3784
4. Database BIOSIS [Online] Biosciences Information Service, Philadelphia, PA, US; September 1998, Squadrito Giuseppe L. et al., "Oxidative chemistry of nitric oxide: The roles of

superoxide, peroxyxynitrite, and carbon dioxide" Database Accession No. PREV1 99800442902; & FREE RADICAL BIOLOGY AND MEDICINE, Vol. 25, No. 4-5, September 1998, pages 392-493, ISSN: 0891-5849

5. WO 98/29417 A1

6. U.S. Patent No. 4,757,063

7. EP 0826370 A1

8. Wendel A. et al., "A novel biologically active seleno-organic compound-VI - Protection by ebselen (PZ 51) against galactosamine/endotoxin-induced hepatitis in mice" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, Vol. 35, No. 13, 1 July 1986, pages 2115-2118, XP0238481 94 ISSN: 0006-2952 [retrieved on 1986-07-01]

9. WO 96/33712 A1

10. DE 36 38 124 A1

Applicants note that U.S. Patent No. 4,618,669 and U.S. Patent No. 4,730,053 have previously been submitted in the Information Disclosure Statement filed January 29, 2002, and U.S. Patent No. 4,757,063 and WO 96/33712 A1 have previously been submitted in the Supplemental Information Disclosure Statement filed September 28, 2005. Accordingly, copies of these documents are not being resubmitted and are not being listed on the Form PTO-1449 submitted herewith.

Since this Fifth Supplemental Information Disclosure Statement is being submitted subsequent to allowance of the allowance and prior to payment of the issue fee, Applicants have provided below a Statement Under 37 C.F.R. § 1.97(e), and payment in the amount of \$180.00 to cover the fee set forth in 37 C.F.R. § 1.17(p) is being submitted herewith in accordance with 37

C.F.R. § 1.97. However, authorization is hereby provided to charge payment of any necessary fee associated with this communication or credit any overpayment to Deposit Account No. 19-0089.

In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement. Of course, this statement does not apply to information that has previously been cited by Applicants or the Examiner in the present application as that information is already of record and no certification is necessary.

Copies of the above-noted documents 3-5, 7, 8 and 10 are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider these documents along with the European Office Action, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.


As noted above, Applicants enclose \$180.00 in payment of the fee for consideration of this Information Disclosure Statement. If any fee is needed for consideration of the this paper and the information cited therein, authorization is hereby provided to charge any required fee, including any fee under 37 C.F.R. 1.17(p), to Deposit Account No. 19-0089.

P21480

Application No. 09/926,218

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,  
Arne HOLMGREN et al.



Arnold Turk  
Reg. No. 33,094

December 22, 2009  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Arnold Turk  
Reg. No. 33094